

# Mario Scartozzi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/467829/publications.pdf>

Version: 2024-02-01

312  
papers

6,729  
citations

71102

41  
h-index

98798

67  
g-index

324  
all docs

324  
docs citations

324  
times ranked

9539  
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognostic Role of a New Index Tested in European and Korean Advanced Biliary Tract Cancer Patients: the PECS Index. <i>Journal of Gastrointestinal Cancer</i> , 2022, 53, 289-298.	1.3	6
2	Clinical insights and prognostic factors from an advanced biliary tract cancer case series: a real-world analysis. <i>Journal of Chemotherapy</i> , 2022, 34, 123-132.	1.5	1
3	Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 865-874.	4.2	11
4	Colorectal cancer promoter methylation alteration affects the expression of glutamate ionotropic receptor AMPA type subunit 4 alternative isoforms potentially relevant in colon tissue. <i>Human Cell</i> , 2022, 35, 310-319.	2.7	8
5	Extensive molecular profiling of squamous cell anal carcinoma in a phase 2 trial population: Translational analyses of the "CARACAS" study. <i>Journal of Clinical Oncology</i> , 2022, 40, 5-5.	1.6	1
6	Mismatch repair proteins (MMR) expression as predictive factor in locally advanced rectal cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 182-182.	1.6	0
7	HOXD8 hypermethylation as a fully sensitive and specific biomarker for biliary tract cancer detectable in tissue and bile samples. <i>British Journal of Cancer</i> , 2022, 126, 1783-1794.	6.4	12
8	The role of immune checkpoint inhibitors in the treatment sequence of advanced gastric or gastro-esophageal junction cancer: A systematic review and meta-analysis of randomized trials. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 173, 103674.	4.4	17
9	Risk-adjusted analysis of survival variability among hospitals treating biliary malignancy. <i>Journal of Chemotherapy</i> , 2022, 34, 543-549.	1.5	1
10	Encorafenib plus cetuximab treatment in BRAF V600E-mutated metastatic colorectal cancer patients pre-treated with an anti-EGFR: An AGEO-GONO case series. <i>European Journal of Cancer</i> , 2022, 168, 34-40.	2.8	4
11	Predictive significance of circulating histones in hepatocellular carcinoma patients treated with sorafenib. <i>Epigenomics</i> , 2022, 14, 507-517.	2.1	4
12	Renal Function Outcomes in Metastatic Non-Small-Cell Lung Carcinoma Patients Treated with Chemotherapy or Immune Checkpoint Inhibitors: An Unexpected Scenario. <i>Vaccines</i> , 2022, 10, 679.	4.4	4
13	Liquid Biopsy-Driven Cetuximab Rechallenge Strategy in Molecularly Selected Metastatic Colorectal Cancer Patients. <i>Frontiers in Oncology</i> , 2022, 12, 852583.	2.8	6
14	How to improve metastatic pancreatic ductal adenocarcinoma patients' selection: Between clinical trials and the real-world. <i>World Journal of Clinical Oncology</i> , 2022, 13, 417-422.	2.3	0
15	Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: An international study. <i>Journal of Clinical Oncology</i> , 2022, 40, 4069-4069.	1.6	5
16	From bench to bedside and back: prognostic groups of Phase 2 study of second-line FOLFIRI-aflibercept in prospectively stratified, RAS wild type, anti-EGFR resistant, metastatic colorectal cancer patients: The DISTINCTIVE trial "A GISCAD study. <i>Journal of Clinical Oncology</i> , 2022, 40, e15571-e15571.	1.6	0
17	Influence of type 2 diabetes mellitus and concomitant anti-diabetic medications in patients with metastatic pancreatic ductal adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2022, 40, e16301-e16301.	1.6	0
18	EGFR-Mutated Non-Small Cell Lung Cancer and Resistance to Immunotherapy: Role of the Tumor Microenvironment. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6489.	4.1	45

#	ARTICLE	IF	CITATIONS
19	Lymphocyte to monocyte ratio in metastatic pancreatic ductal adenocarcinoma as a prognostic factor and its potential role in identifying a subset of patients with a favorable response to therapy.. Journal of Clinical Oncology, 2022, 40, 4153-4153.	1.6	0
20	Retrospective survival analysis in patients with metastatic pancreatic ductal adenocarcinoma with insulin-treated type 2 diabetes mellitus. Tumori, 2021, 107, 550-555.	1.1	5
21	Introducing immunotherapy for advanced hepatocellular carcinoma patients: Too early or too fast?. Critical Reviews in Oncology/Hematology, 2021, 157, 103167.	4.4	30
22	Combining Immunotherapy with Anti-angiogenic Therapy: The New Standard of Care for Hepatocellular Cancer?. Journal of Clinical Oncology and Therapeutics, 2021, 3, .	0.1	1
23	Lenvatinib versus sorafenib in firstâ€line treatment of unresectable hepatocellular carcinoma: An inverse probability of treatment weighting analysis. Liver International, 2021, 41, 1389-1397.	3.9	45
24	P30.02 Assessing SIADH (Syndrome of Inappropriate Antidiuretic Hormone Secretion) Management and Outcome Among Lung Cancer Patients: The Assert Trial. Journal of Thoracic Oncology, 2021, 16, S394-S395.	1.1	0
25	Sequential Treatment of Sorafenibâ€“Regorafenib Versus Sorafenibâ€“Physicianâ€™s Choice: A Propensity Score-Matched Analysis. Targeted Oncology, 2021, 16, 401-410.	3.6	5
26	2P Role of neutrophil-to-lymphocyte ratio (NLR) in the outcome of NSCLC EGFR mutated. Journal of Thoracic Oncology, 2021, 16, S699-S700.	1.1	1
27	The Role of p53 Expression in Patients with RAS/BRAF Wild-Type Metastatic Colorectal Cancer Receiving Irinotecan and Cetuximab as Later Line Treatment. Targeted Oncology, 2021, 16, 517-527.	3.6	7
28	Are All Anti-Angiogenic Drugs the Same in the Treatment of Second-Line Metastatic Colorectal Cancer? Expert Opinion on Clinical Practice. Frontiers in Oncology, 2021, 11, 637823.	2.8	8
29	A Novel Prognostic Tool in Western and Eastern Biliary Tract Cancer Patients Treated in First-line Setting: the ECSIPOT Index. Journal of Gastrointestinal Cancer, 2021, , 1.	1.3	0
30	Phase 2 study of second-line FOLFIRI-aflibercept in prospectively stratified, RAS wild type, anti-EGFR resistant, metastatic colorectal cancer patients: The DISTINCTIVE trial.. Journal of Clinical Oncology, 2021, 39, e15503-e15503.	1.6	0
31	Liquid biopsy-driven anti-EGFR rechallenge in patients with metastatic colorectal cancer.. Journal of Clinical Oncology, 2021, 39, 3577-3577.	1.6	2
32	The association between Major Depressive Disorder and premature death risk in hematologic and solid cancer: a longitudinal cohort study. Journal of Public Health Research, 2021, 10, .	1.2	2
33	Impact of Aspirin on clinical outcome in advanced HCC patients receiving sorafenib and regorafenib. Hpb, 2021, 23, 915-920.	0.3	14
34	P-128 Influence of anti-diabetic medications on the outcomes of patients with pancreatic ductal adenocarcinoma and type 2 diabetes mellitus. Annals of Oncology, 2021, 32, S142.	1.2	0
35	P-129 Concomitant RAS and BRAF mutations: Impact on overall survival and progression free survival in metastatic colorectal cancer patients. Annals of Oncology, 2021, 32, S142-S143.	1.2	0
36	Long Term Survival With Regorafenib: REALITY (Real Life in Italy) Trial - A GISCAD Study. Clinical Colorectal Cancer, 2021, , .	2.3	0

#	ARTICLE	IF	CITATIONS
37	BRCA-mutant pancreatic ductal adenocarcinoma. British Journal of Cancer, 2021, 125, 1321-1332.	6.4	15
38	A prognostic model in patients with advanced biliary tract cancer receiving first-line chemotherapy. Acta Oncologica, 2021, 60, 1317-1324.	1.8	2
39	P-127 Lymphocyte to monocyte ratio as a prognostic factor in stage IV pancreatic ductal adenocarcinoma naive patients before gemcitabine-nab-paclitaxel chemotherapy. Annals of Oncology, 2021, 32, S142.	1.2	0
40	PD-5 Retrospective comparative analysis of K-ras G12C vs other K-ras mutations in metastatic colorectal cancer patients treated with first-line chemotherapy doublet + bevacizumab. Annals of Oncology, 2021, 32, S200.	1.2	0
41	Molecular-driven treatment for biliary tract cancer: the promising turning point. Expert Review of Anticancer Therapy, 2021, 21, 1253-1264.	2.4	0
42	467P Monocyte to red blood cells ratio (MRR): an innovative haematologic prognostic parameter in FOLFIRI-aflibercept treated patients: A subgroup analysis from the DISTINCTIVE trial. Annals of Oncology, 2021, 32, S565.	1.2	0
43	Lenvatinib versus Sorafenib as first-line treatment in hepatocellular carcinoma: A multi-institutional matched case-control study. Hepatology Research, 2021, 51, 1229-1241.	3.4	33
44	Emerging treatment evolutions and integrated molecular characteristics of biliary tract cancers. Cancer Science, 2021, 112, 4819-4833.	3.9	4
45	1479P Exploring second-line therapy outcome in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRCA1-2pv). Annals of Oncology, 2021, 32, S1092.	1.2	0
46	459P Dynamic changes of pro-angiogenic factors during FOLFIRI-aflibercept treatment: Interim analysis of DISTINCTIVE trial. Annals of Oncology, 2021, 32, S562.	1.2	0
47	Retrospective Comparative Analysis of KRAS G12C vs. Other KRAS Mutations in mCRC Patients Treated With First-Line Chemotherapy Doublet + Bevacizumab. Frontiers in Oncology, 2021, 11, 736104.	2.8	8
48	440P Response to BRAF inhibitors combined with anti-EGFR after previous anti-EGFR exposure for BRAF V600E mutant metastatic colorectal cancer patients. Annals of Oncology, 2021, 32, S554.	1.2	1
49	417P Liquid biopsy driven anti-EGFR rechallenge in metastatic colorectal cancer. Annals of Oncology, 2021, 32, S543-S544.	1.2	1
50	490P New horizons in metastatic colorectal cancer: Role of CD44 expression. Annals of Oncology, 2021, 32, S573-S574.	1.2	0
51	A review of immune checkpoint blockade in breast cancer. Seminars in Oncology, 2021, 48, 208-225.	2.2	11
52	407P Neoadjuvant chemo-radiotherapy response in patients affected by mismatch repair deficient (dMMR) locally advanced rectal cancer. Annals of Oncology, 2021, 32, S539-S540.	1.2	0
53	Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter survey. ESMO Open, 2021, 6, 100238.	4.5	12
54	Cholangiocarcinoma: new perspectives for new horizons. Expert Review of Gastroenterology and Hepatology, 2021, 15, 1367-1383.	3.0	13

#	ARTICLE	IF	CITATIONS
55	Uncovering key targets of success for immunotherapy in pancreatic cancer. Expert Opinion on Therapeutic Targets, 2021, 25, 987-1005.	3.4	8
56	Randomized phase II trial of avelumab alone or in combination with cetuximab for patients with previously treated, locally advanced, or metastatic squamous cell anal carcinoma: the CARACAS study. , 2021, 9, e002996.		24
57	The Reliability and Test-Retest Stability of the Treatment Perception Questionnaire (TPQ) in the Oncology Field: A Pilot Study. Clinical Practice and Epidemiology in Mental Health, 2021, 17, 324-330.	1.2	1
58	The Difficult Task of Diagnosing Depression in Elderly People with Cancer: A Systematic Review. Clinical Practice and Epidemiology in Mental Health, 2021, 17, 295-306.	1.2	3
59	The Quality of Life of People with Solid Cancer is Less Worse than Other Diseases with better Prognosis, Except in the Presence of Depression. Clinical Practice and Epidemiology in Mental Health, 2021, 17, 315-323.	1.2	4
60	SOFT TISSUE EPITHELIOID VASCULAR TUMORS: A PRACTICAL CLINICO PATHOLOGICAL DIAGNOSTIC APPROACH. , 2021, 01, 242.		0
61	Why precision medicine should be applied across the continuum of care for metastatic colorectal cancer patients?. Future Oncology, 2020, 16, 4337-4339.	2.4	11
62	The prognostic nutritional index predicts survival and response to firstâ€line chemotherapy in advanced biliary cancer. Liver International, 2020, 40, 704-711.	3.9	42
63	Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma. Targeted Oncology, 2020, 15, 773-785.	3.6	12
64	447P Long term survival with regorafenib: REALITY (real life in Italy) trial - A GISCAD Study. Annals of Oncology, 2020, 31, S432.	1.2	0
65	Validation and refinement of PROSASH model using the neutrophilâ€lymphocyte ratio in patients with HCC receiving sorafenib. Liver Cancer International, 2020, 1, 6-11.	1.3	0
66	3P Association between inflammation index and nutritional status and the effectiveness of immunotherapy in NSCLC treatment. Annals of Oncology, 2020, 31, S1418.	1.2	0
67	Anti-EGFR Therapy in Metastatic Small Bowel Adenocarcinoma: Myth or Reality?. Clinical Medicine Insights: Oncology, 2020, 14, 117955492094669.	1.3	9
68	65P Prognostic role of PECS2 index in advanced biliary tract cancer (BTC) patients treated with first line chemotherapy: Training and validation cohorts. Annals of Oncology, 2020, 31, S266.	1.2	0
69	Gold Nanoparticles: A New Golden Era in Oncology?. Pharmaceuticals, 2020, 13, 192.	3.8	30
70	402MO Final results of the CARACAS study: Randomized phase II trial of avelumab alone or with cetuximab for unresectable, locally advanced or metastatic squamous cell anal carcinoma progressed to at least one line of treatment. Annals of Oncology, 2020, 31, S412.	1.2	14
71	767P Neutrophil-to-lymphocyte ratio (NLR) and systemic inflammation index (SII) as prognostic factors in advanced urinary tract carcinoma patients treated with atezolizumab: Subanalysis of the Italian population of the SAUL study. Annals of Oncology, 2020, 31, S592.	1.2	0
72	Molecular-Biology-Driven Treatment for Metastatic Colorectal Cancer. Cancers, 2020, 12, 1214.	3.7	26

#	ARTICLE	IF	CITATIONS
73	Association of <i>NOS3</i> and <i>ANGPT2</i> Gene Polymorphisms with Survival in Patients with Hepatocellular Carcinoma Receiving Sorafenib: Results of the Multicenter Prospective INNOVATE Study. <i>Clinical Cancer Research</i> , 2020, 26, 4485-4493.	7.0	13
74	The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib. <i>PLoS ONE</i> , 2020, 15, e0232449.	2.5	29
75	From CENTRAL to SENTRAL (SERum aNgiogenesis cenTRAL): Circulating Predictive Biomarkers to Anti-VEGFR Therapy. <i>Cancers</i> , 2020, 12, 1330.	3.7	7
76	Fluoropyrimidine single agent or doublet chemotherapy as second line treatment in advanced biliary tract cancer. <i>International Journal of Cancer</i> , 2020, 147, 3177-3188.	5.1	17
77	Utility of neutrophil-to-lymphocyte ratio to identify long-term survivors among HCC patients treated with sorafenib. <i>Medicine (United States)</i> , 2020, 99, e19958.	1.0	13
78	Is There an Optimal Choice in Refractory Colorectal Cancer? A Network Meta-Analysis. <i>Clinical Colorectal Cancer</i> , 2020, 19, 82-90.e9.	2.3	6
79	Colorectal Cancer Early Detection in Stool Samples Tracing CpG Islands Methylation Alterations Affecting Gene Expression. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4494.	4.1	24
80	Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study. <i>Targeted Oncology</i> , 2020, 15, 115-126.	3.6	15
81	Retreatment With Anti-EGFR Antibodies in Metastatic Colorectal Cancer Patients: A Multi-institutional Analysis. <i>Clinical Colorectal Cancer</i> , 2020, 19, 191-199.e6.	2.3	20
82	Immune Checkpoint Inhibitors in the Treatment of HCC. <i>Frontiers in Oncology</i> , 2020, 10, 601240.	2.8	77
83	Thyroid hormones ratio is a major prognostic marker in advanced metastatic colorectal cancer: Results from the phase III randomised CORRECT trial. <i>European Journal of Cancer</i> , 2020, 133, 66-73.	2.8	19
84	First-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS-BRAF wild-type metastatic colorectal cancer elderly patients: The PANDA study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4002-4002.	1.6	28
85	Randomized phase II trial of avelumab alone or with cetuximab for unresectable, locally advanced or metastatic squamous cell anal carcinoma progressed to at least one line of treatment: The CARACAS study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4051-4051.	1.6	1
86	Observational retrospective evaluation of treatment with liposomal irinotecan plus fluorouracil/leucovorin for metastatic pancreatic cancer patients: An Italian large real-world analysis.. <i>Journal of Clinical Oncology</i> , 2020, 38, 660-660.	1.6	3
87	Health Related Quality of Life in Patients with Onco-hematological Diseases. <i>Clinical Practice and Epidemiology in Mental Health</i> , 2020, 16, 174-179.	1.2	15
88	Defining the metabolomic profile associated with early cardiotoxicity in patients with breast cancer treated with anthracyclines. <i>European Heart Journal</i> , 2020, 41, .	2.2	4
89	The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib. , 2020, 15, e0232449.		0
90	The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib. , 2020, 15, e0232449.		0

#	ARTICLE	IF	CITATIONS
91	The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib. , 2020, 15, e0232449.		0
92	The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib. , 2020, 15, e0232449.		0
93	Overall survival and progression-free survival in metastatic colorectal cancer patients with concomitant RAS and BRAF mutations: a single center experience. Annals of Oncology, 2019, 30, iv81.	1.2	0
94	A validated prognostic classifier for BRAF-mutated metastatic colorectal cancer: the "BRAF BeCool"™ study. European Journal of Cancer, 2019, 118, 121-130.	2.8	51
95	Is there an optimal choice in refractory colorectal cancer? A network meta-analysis. Annals of Oncology, 2019, 30, iv14.	1.2	1
96	Clustered protocadherins methylation alterations in cancer. Clinical Epigenetics, 2019, 11, 100.	4.1	33
97	ANGPT2 and NOS3 Polymorphisms and Clinical Outcome in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib. Cancers, 2019, 11, 1023.	3.7	23
98	Effectiveness of CA 19.9 in predicting prognosis in metastatic pancreatic cancer patients treated with nab-paclitaxel plus gemcitabine. Annals of Oncology, 2019, 30, iv63.	1.2	0
99	A new prognostic score for biliary tract cancer: a multicenter experience. Annals of Oncology, 2019, 30, iv92.	1.2	0
100	Multicentric prospective study of validation of angiogenesis-related gene polymorphisms in hepatocellular carcinoma patients treated with sorafenib: results of INNOVATE study. Annals of Oncology, 2019, 30, iv113.	1.2	0
101	Efficacy of retreatment with anti-EGFRs in metastatic colorectal cancer is not predictable by clinical factors related to prior lines of therapy: a multi-institutional analysis. Annals of Oncology, 2019, 30, iv118.	1.2	0
102	Correlation between p53 expression and clinical outcome in RAS/BRAF wild type metastatic colorectal cancer patients receiving later-line irinotecan-cetuximab. Annals of Oncology, 2019, 30, v226.	1.2	0
103	Multicentric prospective study of validation of angiogenesis-related gene polymorphisms in HCC patients treated with sorafenib: Final results of INNOVATE study. Annals of Oncology, 2019, 30, v287.	1.2	1
104	ASSERT: A prospective, observational study measuring sodium improvement and outcomes in patients treated for moderate to severe hyponatremia secondary to syndrome of inappropriate antidiuretic hormone secretion (SIADH) in Italy (lung cancer cohort). Annals of Oncology, 2019, 30, v742.	1.2	0
105	New therapeutic targets in pancreatic cancer. Cancer Treatment Reviews, 2019, 81, 101926.	7.7	74
106	Sorafenib in patients with hepatocellular carcinoma: 10 years of real life. Annals of Oncology, 2019, 30, iv57.	1.2	0
107	Systemic therapy for the treatment of endometrial cancer. Expert Opinion on Pharmacotherapy, 2019, 20, 2019-2032.	1.8	29
108	Impact of Baseline Characteristics on the Overall Survival of HCC Patients Treated with Sorafenib: Ten Years of Experience. Gastrointestinal Tumors, 2019, 6, 92-107.	0.7	22

#	ARTICLE	IF	CITATIONS
109	&lt;p&gt;Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: training and validation cohort with online calculator (ARC: Anal Cancer Response) Tj ETQq1 1 0.7849 14 rgBT4 Overlook	1.1	7
110	Safe chemotherapy for treating early breast cancer in G6PD-deficient patients. <i>Annals of Oncology</i> , 2019, 30, iii33.	1.2	0
111	Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations. <i>European Journal of Cancer</i> , 2019, 111, 94-106.	2.8	36
112	The Italian Rare Pancreatic Exocrine Cancer Initiative. <i>Tumori</i> , 2019, 105, 353-358.	1.1	7
113	The prognostic impact of primary tumour location in patients with stage II and stage III colon cancer receiving adjuvant therapy. A GISCAD analysis from three large randomised trials. <i>European Journal of Cancer</i> , 2019, 111, 1-7.	2.8	12
114	Prognostic Role of a New Index (RAPID Index) in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib: Training and Validation Cohort. <i>Gastrointestinal Tumors</i> , 2019, 6, 71-80.	0.7	4
115	Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study. <i>Journal of Geriatric Oncology</i> , 2019, 10, 591-597.	1.0	6
116	Next generation sequencing driven successful combined treatment with laparoscopic surgery and immunotherapy for relapsed stage IVB cervical and synchronous stage IV lung cancer. <i>Oncotarget</i> , 2019, 10, 2012-2021.	1.8	3
117	A randomized phase II study comparing cabazitaxel/prednisone to cabazitaxel alone in docetaxel-pretreated men with metastatic castration resistant prostate cancer (mCRPC): The CABACARE trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS345-TPS345.	1.6	0
118	RISE-HEP project part 1: Treatment sequences evaluation in hepatocellular carcinoma cell lines.. <i>Journal of Clinical Oncology</i> , 2019, 37, e15663-e15663.	1.6	0
119	Assessment of ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients (pts) with advanced HER2-negative gastric or gastroesophageal junction cancers: The ARMANI phase III trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS4151-TPS4151.	1.6	0
120	Efficacy of retreatment with anti-EGFRs in mCRC is not predictable by clinical factors related to prior lines of therapy: A multi-institutional analysis.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3540-3540.	1.6	0
121	Multicentric prospettive study of validation of angiogenesis-related gene polymorphisms in hepatocellular carcinoma patients treated with sorafenib: Interim analysis of INNOVATE study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4075-4075.	1.6	0
122	Microenvironmental M1 tumor-associated macrophage polarization influences cancer-related anemia in advanced ovarian cancer: key role of interleukin-6. <i>Haematologica</i> , 2018, 103, e388-e391.	3.5	31
123	Bone metastases in biliary cancers: A multicenter retrospective survey. <i>Journal of Bone Oncology</i> , 2018, 12, 33-37.	2.4	5
124	BRAF-mutant colorectal cancer, a different breed evolving. <i>Expert Review of Molecular Diagnostics</i> , 2018, 18, 499-512.	3.1	19
125	Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?. <i>World Journal of Gastroenterology</i> , 2018, 24, 4152-4163.	3.3	134
126	CALGB 80101 and the Final Call for Preoperative Chemotherapy in Gastric Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 1178-1179.	1.6	3



#	ARTICLE	IF	CITATIONS
127	Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An INNOVATE study protocol. <i>Tumori</i> , 2018, 104, 476-479.	1.1	14
128	Systemic Chemotherapy for Advanced Rare Pancreatic Histotype Tumors. <i>Pancreas</i> , 2018, 47, 759-771.	1.1	29
129	Clinical and circulating biomarkers of survival and recurrence after radiofrequency ablation in patients with hepatocellular carcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 129, 44-53.	4.4	23
130	The prognostic role of hemoglobin levels in patients undergoing concurrent chemo-radiation for anal cancer. <i>Radiation Oncology</i> , 2018, 13, 83.	2.7	23
131	Prognostic Value of Thyroid Hormone Ratios in Patients With Advanced Metastatic Colorectal Cancer Treated With Regorafenib: The ATOREADOR Study. <i>Clinical Colorectal Cancer</i> , 2018, 17, e601-e615.	2.3	18
132	CREAM study: Clinical correlation between immunotherapy-Related clinical outcome and intestinal microbiote in metastatic patients.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS215-TPS215.	1.6	0
133	Prediction of overall survival with 2nd-line (L2OS) chemotherapy (CT) in patients (Pts) with advanced biliary tract cancer (aBTC): AGEO CT2BIL cohort update and international multicenter external validations.. <i>Journal of Clinical Oncology</i> , 2018, 36, e16119-e16119.	1.6	0
134	Mismatch repair deficiency may affect clinical outcome through immune response activation in metastatic gastric cancer patients receiving first-line chemotherapy. <i>Gastric Cancer</i> , 2017, 20, 156-163.	5.3	62
135	Tumor infiltrating lymphocytes in gastrointestinal tumors: Controversies and future clinical implications. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 110, 106-116.	4.4	33
136	The immune infiltrate in prostate, bladder and testicular tumors: An old friend for new challenges. <i>Cancer Treatment Reviews</i> , 2017, 53, 138-145.	7.7	20
137	Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: a retrospective study. <i>Scientific Reports</i> , 2017, 7, 42499.	3.3	30
138	Multimodal treatment of resectable pancreatic ductal adenocarcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 111, 152-165.	4.4	28
139	Regorafenib-induced hypothyroidism and cancer-related fatigue: is there a potential link?. <i>European Journal of Endocrinology</i> , 2017, 177, 85-92.	3.7	23
140	Second-line chemotherapy for advanced pancreatic cancer: Which is the best option?. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 115, 1-12.	4.4	26
141	Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of randomized controlled trials. <i>Cancer Treatment Reviews</i> , 2017, 57, 8-15.	7.7	75
142	Interplay Between SIRT-3, Metabolism and Its Tumor Suppressor Role in Hepatocellular Carcinoma. <i>Digestive Diseases and Sciences</i> , 2017, 62, 1872-1880.	2.3	13
143	The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab. <i>British Journal of Cancer</i> , 2017, 117, 315-321.	6.4	19
144	Off-target effects and clinical outcome in metastatic colorectal cancer patients receiving regorafenib: The TRIBUTE analysis. <i>Scientific Reports</i> , 2017, 7, 45703.	3.3	22

#	ARTICLE	IF	CITATIONS
145	Immunotherapy for colorectal cancer: where are we heading?. Expert Opinion on Biological Therapy, 2017, 17, 709-721.	3.1	85
146	Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world. Gastric Cancer, 2017, 20, 825-833.	5.3	32
147	Selecting patients for gastrectomy in metastatic esophago-gastric cancer: clinics and pathology are not enough. Future Oncology, 2017, 13, 2265-2275.	2.4	10
148	Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale. European Journal of Cancer, 2017, 86, 106-114.	2.8	76
149	First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: final results of the GISCAD (Italian Group for the Study of) Tj ETQq1 1 0.784314,rgBT /Overlock 10117. 1099-1104.	6.4	11
150	Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy. Oncologist, 2017, 22, 1463-1469.	3.7	27
151	Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients. European Journal of Cancer, 2017, 83, 106-115.	2.8	25
152	Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma. Targeted Oncology, 2017, 12, 795-803.	3.6	23
153	Aggressive differentiated thyroid cancer with multiple metastases and NRAS and TERT promoter mutations: A case report. Oncology Letters, 2017, 14, 2186-2190.	1.8	3
154	Timing of the negative effects of trastuzumab on cardiac mechanics after anthracycline chemotherapy. International Journal of Cardiovascular Imaging, 2017, 33, 197-207.	1.5	10
155	The Role of Aspirin as Antitumoral Agent for Heavily Pretreated Patients With Metastatic Colorectal Cancer Receiving Capecitabine Monotherapy. Clinical Colorectal Cancer, 2017, 16, 38-43.	2.3	18
156	Immunotherapeutic approaches for hepatocellular carcinoma. Oncotarget, 2017, 8, 33897-33910.	1.8	50
157	FOLFOX4/XELOX in stage II&#x2013;III colon cancer: Efficacy results of the Italian three or six colon adjuvant (TOSCA) trial.. Journal of Clinical Oncology, 2017, 35, 3501-3501.	1.6	6
158	Ang-2 polymorphisms in relation to outcome in advanced HCC patients receiving sorafenib.. Journal of Clinical Oncology, 2017, 35, e15666-e15666.	1.6	3
159	Antiangiogenic agents after first line and sorafenib plus chemoembolization: a systematic review. Oncotarget, 2017, 8, 66699-66708.	1.8	11
160	Molecular classifications of gastric cancers: Novel insights and possible future applications. World Journal of Gastrointestinal Oncology, 2017, 9, 194.	2.0	46
161	The role of sidedness, EGFR gene copy number (GCN) and EGFR promoter methylation in RAS/BRAF wild type (WT) colorectal cancer (CRC) patients receiving irinotecan/cetuximab.. Journal of Clinical Oncology, 2017, 35, 628-628.	1.6	0
162	Prognostic neutrophil-to-lymphocyte ratio in head and neck cancer: A single center experience.. Journal of Clinical Oncology, 2017, 35, e17540-e17540.	1.6	0

#	ARTICLE	IF	CITATIONS
163	Metformin effects on clinical outcome in advanced HCC patients receiving sorafenib: Validation study.. Journal of Clinical Oncology, 2017, 35, e15684-e15684.	1.6	0
164	Prognostic value of neutrophil-to-lymphocyte ratio in advanced EGFR-mutated non-small cell lung cancer (NSCLC) treated with a tyrosine-kinase inhibitors: A retrospective analysis in a series of western patients.. Journal of Clinical Oncology, 2017, 35, e23045-e23045.	1.6	0
165	HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives. Oncotarget, 2016, 7, 69060-69074.	1.8	29
166	Lactate Dehydrogenase in Hepatocellular Carcinoma: Something Old, Something New. BioMed Research International, 2016, 2016, 1-7.	1.9	45
167	Efficacy of sorafenib in BRAF-mutated non-small-cell lung cancer (NSCLC) and no response in synchronous BRAF wild type-hepatocellular carcinoma: a case report. BMC Cancer, 2016, 16, 429.	2.6	28
168	No evidence of NRAS mutation in squamous cell anal carcinoma (SCAC). Scientific Reports, 2016, 6, 37621.	3.3	7
169	The Immune Revolution in Gastrointestinal Tumours: Leading the Way or Just Following?. Targeted Oncology, 2016, 11, 593-603.	3.6	14
170	Ramucirumab for the treatment of gastric cancers, colorectal adenocarcinomas, and other gastrointestinal malignancies. Expert Review of Clinical Pharmacology, 2016, 9, 877-885.	3.1	11
171	Prognostic role of KRAS mutations in Sardinian patients with colorectal carcinoma. Oncology Letters, 2016, 12, 1415-1421.	1.8	3
172	Phase III trial comparing 3â€“6 months of adjuvant FOLFOX4/XELOX in stage IIâ€“III colon cancer: safety and compliance in the TOSCA trial. Annals of Oncology, 2016, 27, 2074-2081.	1.2	44
173	Aspirin and Cancer Risk. JAMA Oncology, 2016, 2, 1371.	7.1	0
174	Aflibercept, a New Way to Target Angiogenesis in the Second Line Treatment of Metastatic Colorectal Cancer (mCRC). Targeted Oncology, 2016, 11, 489-500.	3.6	22
175	Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study. Journal of Translational Medicine, 2016, 14, 292.	4.4	43
176	Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients. Scientific Reports, 2016, 6, 25195.	3.3	25
177	The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy. Scientific Reports, 2016, 6, 24136.	3.3	22
178	Clinical impact of tumoral angiogenesis on renal cell carcinoma management: where do we stand?. Expert Review of Precision Medicine and Drug Development, 2016, 1, 229-231.	0.7	4
179	Hypothyroidism and Thyroid Autoimmunity as a Prognostic Biomarker of Better Response in Metastatic Cancer Long-Term Survivors Treated with Sunitinib. Thyroid, 2016, 26, 1336-1337.	4.5	5
180	Second-line angiogenesis inhibition in metastatic colorectal cancer patients: Straightforward or overcrowded?. Critical Reviews in Oncology/Hematology, 2016, 100, 99-106.	4.4	11

#	ARTICLE	IF	CITATIONS
181	Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib. <i>Oncotarget</i> , 2016, 7, 67142-67149.	1.8	91
182	Early onset of hypertension and serum electrolyte changes as potential predictive factors of activity in advanced HCC patients treated with sorafenib: results from a retrospective analysis of the HCC-AVR group. <i>Oncotarget</i> , 2016, 7, 15243-15251.	1.8	26
183	<i>e</i> NOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: final results of the ePHAS study. <i>Oncotarget</i> , 2016, 7, 27988-27999.	1.8	30
184	Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma. <i>Oncotarget</i> , 2016, 7, 37599-37607.	1.8	14
185	Prognostic Value for Incidental Antihypertensive Therapy With $\beta$ -Blockers in Metastatic Colorectal Cancer. <i>Medicine (United States)</i> , 2015, 94, e719.	1.0	18
186	The value of lactate dehydrogenase serum levels as a prognostic and predictive factor for advanced pancreatic cancer patients receiving sorafenib. <i>Oncotarget</i> , 2015, 6, 35087-35094.	1.8	40
187	Tracking the 2015 Gastrointestinal Cancers Symposium: bridging cancer biology to clinical gastrointestinal oncology. <i>OncoTargets and Therapy</i> , 2015, 8, 1149.	2.0	5
188	Basal and bevacizumab-based therapy-induced changes of lactate dehydrogenases and fibrinogen levels and clinical outcome of previously untreated metastatic colorectal cancer patients: a multicentric retrospective analysis. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 155-162.	3.1	27
189	Prospective study of a molecular selection profile for RAS wild type colorectal cancer patients receiving irinotecan-cetuximab. <i>Journal of Translational Medicine</i> , 2015, 13, 140.	4.4	6
190	Metronomic chemotherapy from rationale to clinical studies: A dream or reality?. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 95, 46-61.	4.4	64
191	Recent Aspects of Sunitinib Therapy in Patients with Metastatic Clear-Cell Renal Cell Carcinoma: a Systematic Review of the Literature. <i>Current Urology Reports</i> , 2015, 16, 3.	2.2	12
192	The distinctive molecular, pathological and clinical characteristics of <i>BRAF</i> -mutant colorectal tumors. <i>Expert Review of Molecular Diagnostics</i> , 2015, 15, 979-987.	3.1	14
193	Tumor VEGF expression correlates with tumor stage and identifies prognostically different groups in patients with clear cell renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 113.e1-113.e7.	1.6	15
194	Metastatic gastric cancer in the last two decades: goals achieved and future promises. <i>Future Oncology</i> , 2015, 11, 2633-2636.	2.4	5
195	Aspirin as a neoadjuvant agent during preoperative chemoradiation for rectal cancer. <i>British Journal of Cancer</i> , 2015, 113, 1133-1139.	6.4	52
196	Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 2719-2725.	1.8	66
197	Hepatocellular carcinoma treatment over sorafenib: epigenetics, microRNAs and microenvironment. Is there a light at the end of the tunnel?. <i>Expert Opinion on Therapeutic Targets</i> , 2015, 19, 1623-1635.	3.4	58
198	Neutrophil-to-lymphocyte ratio may be associated with the outcome in patients with prostate cancer. <i>SpringerPlus</i> , 2015, 4, 255.	1.2	40

#	ARTICLE	IF	CITATIONS
199	Steps ahead in the treatment of advanced colorectal cancer: past, current and possible future scenarios. <i>Future Oncology</i> , 2015, 11, 2625-2628.	2.4	4
200	Role and mechanisms of resistance of epidermal growth factor receptor antagonists in the treatment of colorectal cancer. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 1185-1198.	4.1	4
201	Prognostic clinical factors in pretreated colorectal cancer patients receiving regorafenib: Implications for clinical management. <i>Oncotarget</i> , 2015, 6, 33982-33992.	1.8	46
202	Prognostic impact of mismatch repair genes germline defects in colorectal cancer patients: are all mutations equal?. <i>Oncotarget</i> , 2015, 6, 38737-38748.	1.8	25
203	eNOS polymorphisms in relation to outcome in advanced HCC patients receiving sorafenib.. <i>Journal of Clinical Oncology</i> , 2015, 33, 230-230.	1.6	0
204	Osteopontin (OPN) and interleukin-6 (IL-6) as predictive biomarkers in HCC receiving loco-regional treatment: Preliminary results.. <i>Journal of Clinical Oncology</i> , 2015, 33, e13501-e13501.	1.6	0
205	Multigene profiling in incidentally- and clinically detected prostate cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, e16107-e16107.	1.6	0
206	LDH serum levels as prognostic and predictive factor in advanced biliary tract cancer patients treated with first line chemotherapy.. <i>Journal of Clinical Oncology</i> , 2015, 33, e15126-e15126.	1.6	0
207	Natural History of Malignant Bone Disease in Hepatocellular Carcinoma: Final Results of a Multicenter Bone Metastasis Survey. <i>PLoS ONE</i> , 2014, 9, e105268.	2.5	33
208	Pharmacogenomics of cetuximab in metastatic colorectal carcinoma. <i>Pharmacogenomics</i> , 2014, 15, 1701-1715.	1.3	4
209	Selected gastrointestinal cancer presentations from the American Society of Clinical Oncology annual meeting 2013 in review: it is not about the destination, it is about the journey. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 143-150.	1.8	7
210	VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: The ALICE study. <i>International Journal of Cancer</i> , 2014, 135, 1247-1256.	5.1	109
211	The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management. <i>BMC Cancer</i> , 2014, 14, 110.	2.6	80
212	The challenge of targeted therapies for gastric cancer patients: the beginning of a long journey. <i>Expert Opinion on Investigational Drugs</i> , 2014, 23, 925-942.	4.1	32
213	The "angiogenetic ladder", step-wise angiogenesis inhibition in metastatic colorectal cancer. <i>Cancer Treatment Reviews</i> , 2014, 40, 934-941.	7.7	16
214	The role of Micro-RNAs in Hepatocellular Carcinoma: From Molecular Biology to Treatment. <i>Molecules</i> , 2014, 19, 6393-6406.	3.8	56
215	LDH serum levels as a predictive factor for global outcome in pretreated colorectal cancer patients receiving regorafenib: Implications for clinical management.. <i>Journal of Clinical Oncology</i> , 2014, 32, 497-497.	1.6	2
216	Beyond RAS: The Role of Epidermal Growth Factor Receptor (EGFR) and its Network in the Prediction of Clinical Outcome During Anti-EGFR Treatment in Colorectal Cancer Patients. <i>Current Drug Targets</i> , 2014, 15, 1225-1230.	2.1	7

#	ARTICLE	IF	CITATIONS
217	Angiogenesis genotyping, LDH serum levels, and treatment efficacy for advanced hepatocellular carcinoma patients receiving sorafenib.. Journal of Clinical Oncology, 2014, 32, 245-245.	1.6	0
218	Cancer stem cells profile and clinical outcome in stage III colon cancer patients receiving adjuvant oxaliplatin-based chemotherapy.. Journal of Clinical Oncology, 2014, 32, 474-474.	1.6	0
219	Tumor angiogenesis genotyping and efficacy of first-line chemotherapy in metastatic gastric cancer patients.. Journal of Clinical Oncology, 2014, 32, 64-64.	1.6	0
220	Correlation of distinctive angiogenetic profiles with clinical outcome for different treatment sequences in mRCC.. Journal of Clinical Oncology, 2014, 32, 474-474.	1.6	0
221	VEGF and VEGFRs polymorphisms analysis in advanced renal cell carcinoma tissues: Is heterogeneity ever the answer?. Journal of Clinical Oncology, 2014, 32, 4533-4533.	1.6	0
222	Angiogenesis polymorphisms profile in the prediction of clinical outcome of advanced HCC patients receiving sorafenib: Combined analysis of VEGF and HIF-1.. Journal of Clinical Oncology, 2014, 32, e15140-e15140.	1.6	0
223	Tumor angiogenesis genotyping and efficacy of first-line chemotherapy in metastatic gastric cancer patients. Pharmacogenomics, 2013, 14, 1991-1998.	1.3	17
224	Molecular biomarkers of resistance to anti-EGFR treatment in metastatic colorectal cancer, from classical to innovation. Critical Reviews in Oncology/Hematology, 2013, 88, 272-283.	4.4	27
225	The Tower of Babel of liver metastases from colorectal cancer: Are we ready for one language?. Critical Reviews in Oncology/Hematology, 2013, 85, 332-341.	4.4	8
226	Role of $\alpha$ 24 integrin in <i>HER-3</i> -negative, <i>K-RAS</i> wild-type metastatic colorectal tumors receiving cetuximab. Future Oncology, 2013, 9, 1207-1214.	2.4	5
227	VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib. British Journal of Cancer, 2013, 108, 1126-1132.	6.4	71
228	The Response of Breast Cancer Cells to Mesenchymal Stem Cells. Plastic and Reconstructive Surgery, 2013, 132, 899e-910e.	1.4	18
229	Clinical Evidence for Three Distinct Gastric Cancer Subtypes: Time for a New Approach. PLoS ONE, 2013, 8, e78544.	2.5	14
230	Cancer Stem Cell Gene Profile as Predictor of Relapse in High Risk Stage II and Stage III, Radically Resected Colon Cancer Patients. PLoS ONE, 2013, 8, e72843.	2.5	36
231	Effect of VEGF and VEGFR polymorphisms on clinical outcome and response in patients with advanced renal cell carcinoma receiving first-line treatment.. Journal of Clinical Oncology, 2013, 31, 388-388.	1.6	1
232	Targeting Hedgehog in pancreatic cancer: An innovative approach but not for all tumors.. Journal of Clinical Oncology, 2013, 31, 205-205.	1.6	0
233	Tumor cancer stem cell genetic profile as predictor of relapse in stage II and III radically resected colon cancer patients.. Journal of Clinical Oncology, 2013, 31, 429-429.	1.6	0
234	Locally advanced or metastatic pancreatic tumors: Molecular biology may help to know it and to select the optimal treatment.. Journal of Clinical Oncology, 2013, 31, 201-201.	1.6	0

#	ARTICLE	IF	CITATIONS
235	The role of tumor vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptors (VEGFR) polymorphisms in the prediction of clinical outcome for advanced hepatocellular carcinoma receiving sorafenib.. Journal of Clinical Oncology, 2013, 31, 208-208.	1.6	0
236	Prognostic value of incidental betablockers use in metastatic colorectal cancer patients receiving first-line treatment.. Journal of Clinical Oncology, 2013, 31, e14610-e14610.	1.6	0
237	Prognostic stratification of k-RAS wild type colorectal cancer patients receiving irinotecan-cetuximab treatment: Preliminary results of a prospective study.. Journal of Clinical Oncology, 2013, 31, 3591-3591.	1.6	0
238	Primary tumor histology and location as predictive factors for clinical outcome in metastatic gastric cancer (GC) patients receiving first-line chemotherapy.. Journal of Clinical Oncology, 2013, 31, e15081-e15081.	1.6	0
239	Correlation between VEGF and VEGF-R polymorphisms, toxicity, and clinical outcome in HCC patients receiving sorafenib.. Journal of Clinical Oncology, 2013, 31, 4123-4123.	1.6	12
240	Antihypertensive therapy with ACE-inhibitors and clinical outcome in metastatic renal cell carcinoma (mRCC) patients.. Journal of Clinical Oncology, 2013, 31, e15536-e15536.	1.6	0
241	VEGF expression and response to sunitinib in patients with metastatic clear cell renal cell carcinoma. Anticancer Research, 2013, 33, 5017-22.	1.1	12
242	Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients. British Journal of Cancer, 2012, 106, 799-804.	6.4	97
243	Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan+ cetuximab. Annals of Oncology, 2012, 23, 1706-1712.	1.2	34
244	Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?. Annals of Oncology, 2012, 23, 2313-2318.	1.2	170
245	Phosphorylated AKT and MAPK expression in primary tumours and in corresponding metastases and clinical outcome in colorectal cancer patients receiving irinotecan-cetuximab. Journal of Translational Medicine, 2012, 10, 71.	4.4	25
246	Phase II study of pharmacogenetic-tailored therapy in elderly colorectal cancer patients. Digestive and Liver Disease, 2012, 44, 74-79.	0.9	3
247	Role of Vascular Endothelial Growth Factor (VEGF) and VEGF-R Genotyping in Guiding the Metastatic Process in pT4a Resected Gastric Cancer Patients. PLoS ONE, 2012, 7, e38192.	2.5	15
248	The Role of LDH Serum Levels in Predicting Global Outcome in HCC Patients Undergoing TACE: Implications for Clinical Management. PLoS ONE, 2012, 7, e32653.	2.5	47
249	Palliative Treatment. , 2012, , 209-214.		0
250	Adjuvant Treatment After Surgical Resection. , 2012, , 187-194.		0
251	Correlation of activated AKT and MAPK expression in liver metastases with clinical outcome in colorectal cancer patients receiving irinotecan/cetuximab treatment.. Journal of Clinical Oncology, 2012, 30, 449-449.	1.6	0
252	The role of tumor vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptors (VEGFR) polymorphisms in the prediction of clinical outcome for advanced hepatocellular carcinoma receiving sorafenib.. Journal of Clinical Oncology, 2012, 30, e14561-e14561.	1.6	0

#	ARTICLE	IF	CITATIONS
253	Angiogenetic pathway as a therapeutic target in renal cell carcinoma. , 2012, 34, 15-22.		1
254	The timing of surgery for resectable metachronous liver metastases from colorectal cancer: Better sooner than later? A retrospective analysis. Digestive and Liver Disease, 2011, 43, 194-198.	0.9	7
255	5-fluorouracil pharmacogenomics: still rocking after all these years?. Pharmacogenomics, 2011, 12, 251-265.	1.3	54
256	Evolving strategies for the treatment of hepatocellular carcinoma: From clinical-guided to molecularly-taylorred therapeutic options. Cancer Treatment Reviews, 2011, 37, 169-177.	7.7	49
257	Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients. British Journal of Cancer, 2011, 104, 1786-1790.	6.4	65
258	Pegylated liposomal doxorubicin, 5-fluorouracil and cisplatin versus mitomycin-C, 5-fluorouracil and cisplatin for advanced gastric cancer: a randomized phase II trial. Cancer Chemotherapy and Pharmacology, 2011, 68, 37-43.	2.3	15
259	Adenocarcinoma arising from ileoanal J-pouch mucosa. Inflammatory Bowel Diseases, 2011, 17, E57-E58.	1.9	1
260	The Role of HER $\beta$ Expression in the Prediction of Clinical Outcome for Advanced Colorectal Cancer Patients Receiving Irinotecan and Cetuximab. Oncologist, 2011, 16, 53-60.	3.7	55
261	Allele polymorphisms of tumor integrins correlate with peritoneal carcinosis capability of gastric cancer cells in radically resected patients. Annals of Oncology, 2011, 22, 897-902.	1.2	9
262	Second-line chemotherapy with irinotecan, 5-fluorouracil and leucovorin (FOLFIRI) in relapsed or metastatic gastric cancer: lessons from clinical practice. Tumori, 2011, 97, 275-9.	1.1	1
263	Novel Perspectives for the Treatment of Gastric Cancer: From a Global Approach to a Personalized Strategy. Current Oncology Reports, 2010, 12, 175-185.	4.0	13
264	Insulin $\beta$ -like growth factor 1 expression correlates with clinical outcome in K $\beta$ RAS wild type colorectal cancer patients treated with cetuximab and irinotecan. International Journal of Cancer, 2010, 127, 1941-1947.	5.1	67
265	Panitumumab: the evidence for its use in the treatment of metastatic colorectal cancer. Core Evidence, 2010, 5, 61.	4.7	11
266	Chemotherapy-Free Intervals in Patients With Metastatic Colorectal Cancer: A Tale of Two Cities?. Journal of Clinical Oncology, 2010, 28, e268-e269.	1.6	1
267	Clinical predictive factors for advanced non-small cell lung cancer (NSCLC) patients receiving third-line therapy: Selecting the unselectable?. Lung Cancer, 2010, 68, 433-437.	2.0	17
268	Trans-arterial chemo-embolization (TACE), with either lipiodol (traditional TACE) or drug-eluting microspheres (precision TACE, pTACE) in the treatment of hepatocellular carcinoma: efficacy and safety results from a large mono-institutional analysis. Journal of Experimental and Clinical Cancer Research, 2010, 29, 164.	8.6	39
269	Locally advanced rectal cancer: from molecular profiling to clinical practice. A literature review: Part 2. Expert Opinion on Pharmacotherapy, 2009, 10, 2467-2478.	1.8	6
270	Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Annals of Oncology, 2009, 20, 227-230.	1.2	294



#	ARTICLE	IF	CITATIONS
271	Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis. <i>BMC Cancer</i> , 2009, 9, 303.	2.6	66
272	Women and lung cancer: Clinical and molecular profiling as a determinate for treatment decisions. <i>Critical Reviews in Oncology/Hematology</i> , 2009, 69, 223-236.	4.4	11
273	Locally Advanced Rectal Cancer Patients Receiving Radio-Chemotherapy: A Novel Clinicalâ€œPathologic Score Correlates With Global Outcome. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 75, 1437-1443.	0.8	4
274	Toward molecularly selected chemotherapy for advanced gastric cancer: State of the art and future perspectives. <i>Cancer Treatment Reviews</i> , 2009, 35, 451-462.	7.7	24
275	Multidisciplinary treatment of locally advanced rectal cancer: a literature review. Part 1. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 2245-2258.	1.8	12
276	PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 2622-2629.	1.6	402
277	Epidermal growth factor receptor gene promoter methylation in primary colorectal tumors and corresponding metastatic sites: a new perspective for an "old" therapeutic target. , 2009, 31, 417-23.		2
278	Pancreatic cancer: Progress in cancer therapy. <i>Critical Reviews in Oncology/Hematology</i> , 2008, 67, 27-38.	4.4	32
279	A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF- $\kappa$ B activation. <i>British Journal of Cancer</i> , 2008, 98, 71-76.	6.4	41
280	Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial. <i>Lancet Oncology</i> , The, 2008, 9, 39-44.	10.7	130
281	Profiling Tumor-Associated Markers for Early Detection of Malignant Mesothelioma: An Epidemiologic Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008, 17, 163-170.	2.5	53
282	Response: Re: Adjuvant Treatment of High-Risk, Radically Resected Gastric Cancer Patients with 5-Fluorouracil, Leucovorin, Cisplatin, and EpiDoxorubicin in a Randomized Controlled Trial. <i>Journal of the National Cancer Institute</i> , 2007, 99, 1346-1347.	6.3	1
283	Nuclear Factor- $\kappa$ B Tumor Expression Predicts Response and Survival in Irinotecan-Refractory Metastatic Colorectal Cancer Treated With Cetuximab-Irinotecan Therapy. <i>Journal of Clinical Oncology</i> , 2007, 25, 3930-3935.	1.6	121
284	Molecular Biology for Stage II Colorectal Cancer: The Jury Is Still Out. <i>Journal of Clinical Oncology</i> , 2007, 25, 2861-2861.	1.6	5
285	COX-2 and NF- $\kappa$ B Overexpression Is Common in Pancreatic Cancer but Does Not Predict for COX-2 Inhibitors Activity in Combination With Gemcitabine and Oxaliplatin. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2007, 30, 526-530.	1.3	34
286	â€œBiliary tract cancers: Molecular profiling as a tool for treatment decisions. A literature reviewâ€• [Cancer Treatment Reviews 32(5) (2006) 333â€œ347]. <i>Cancer Treatment Reviews</i> , 2007, 33, 497.	7.7	0
287	Chemotherapy for advanced gastric cancer: across the years for a standard of care. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 797-808.	1.8	41
288	Epidermal growth factor receptor (EGFR) downstream signalling pathway in primary colorectal tumours and related metastatic sites: optimising EGFR-targeted treatment options. <i>British Journal of Cancer</i> , 2007, 97, 92-97.	6.4	39

#	ARTICLE	IF	CITATIONS
289	Mismatch repair system (MMR) status correlates with response and survival in non-small cell lung cancer (NSCLC) patients. <i>Lung Cancer</i> , 2006, 53, 103-109.	2.0	33
290	Lymphatic, blood vessel and perineural invasion identifies early-stage high-risk radically resected gastric cancer patients. <i>British Journal of Cancer</i> , 2006, 95, 445-449.	6.4	40
291	Anemia may influence the outcome of patients undergoing neo-adjuvant treatment of rectal cancer. <i>Annals of Oncology</i> , 2006, 17, 1661-1664.	1.2	25
292	New target therapies in advanced pancreatic cancer. <i>Annals of Oncology</i> , 2006, 17, v148-v152.	1.2	24
293	Anti-EGFR strategies as an incremental step for the treatment of colorectal cancer patients: moving from scientific evidence to clinical practice. <i>Expert Opinion on Therapeutic Targets</i> , 2006, 10, 281-287.	3.4	4
294	Over-D1 dissection may question the value of radiotherapy as a part of an adjuvant programme in high-risk radically resected gastric cancer patients. <i>British Journal of Cancer</i> , 2005, 92, 1051-1054.	6.4	15
295	Elderly Patients with Advanced Colorectal Cancer: Tolerability and Activity of Chemotherapy. <i>Tumori</i> , 2005, 91, 463-466.	1.1	14
296	Pre-operative treatment modalities in gastric cancer patients. <i>Annals of Oncology</i> , 2005, 16, iv106-iv109.	1.2	0
297	The Role of 5-Fluorouracil (5-FU) Reintroduction with Irinotecan or Oxaliplatin in Truly 5-FU-Refractory Advanced Colorectal Cancer Patients. <i>Oncology</i> , 2005, 68, 212-216.	1.9	4
298	Prognostic Role of Interleukin-1 $\beta$ Gene and Interleukin-1 Receptor Antagonist Gene Polymorphisms in Patients With Advanced Gastric Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 2339-2345.	1.6	56
299	Perioperative anemia and blood transfusions as prognostic factors in patients undergoing resection for non-small cell lung cancers. <i>Lung Cancer</i> , 2005, 49, 371-376.	2.0	36
300	A novel clinical-pathological score correlates with global outcome of locally advanced rectal cancer patients receiving neoadjuvant chemo-radiotherapy. <i>Journal of Clinical Oncology</i> , 2005, 23, 3667-3667.	1.6	0
301	New frontiers in the neoadjuvant therapy of pancreatic adenocarcinoma: apart from therapeutical protocols. <i>JOP: Journal of the Pancreas</i> , 2005, 6, 118-21.	1.5	1
302	Combined analysis of E-cadherin gene (CDH1) promoter hypermethylation and E-cadherin protein expression in patients with gastric cancer: implications for treatment with demethylating drugs. <i>Annals of Oncology</i> , 2004, 15, 489-492.	1.2	47
303	Predictive and Prognostic Role of E-Cadherin Protein Expression in Patients with Advanced Gastric Carcinomas Treated with Palliative Chemotherapy. <i>Tumor Biology</i> , 2004, 25, 106-110.	1.8	15
304	Epidermal Growth Factor Receptor (EGFR) Status in Primary Colorectal Tumors Does Not Correlate With EGFR Expression in Related Metastatic Sites: Implications for Treatment With EGFR-Targeted Monoclonal Antibodies. <i>Journal of Clinical Oncology</i> , 2004, 22, 4772-4778.	1.6	235
305	High curative resection rate with weekly cisplatin, 5-fluorouracil, epidoxorubicin, 6S-leucovorin, glutathione, and filgastrim in patients with locally advanced, unresectable gastric cancer: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). <i>British Journal of Cancer</i> , 2004, 90, 1521-1525.	6.4	58
306	A cost-benefit analysis of chemotherapy for gastric cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2004, 5, 2109-2114.	1.8	2

#	ARTICLE	IF	CITATIONS
307	Molecular biology of sporadic gastric cancer: prognostic indicators and novel therapeutic approaches. <i>Cancer Treatment Reviews</i> , 2004, 30, 451-459.	7.7	65
308	Loss of hMLH1 expression correlates with improved survival in stage III-IV ovarian cancer patients. <i>European Journal of Cancer</i> , 2003, 39, 1144-1149.	2.8	32
309	Elderly Patients with Advanced Non-Small Cell Lung Cancer. <i>Oncology</i> , 2003, 65, 198-203.	1.9	35
310	Mutations of hMLH1 and hMSH2 in Patients With Suspected Hereditary Nonpolyposis Colorectal Cancer: Correlation With Microsatellite Instability and Abnormalities of Mismatch Repair Protein Expression. <i>Journal of Clinical Oncology</i> , 2002, 20, 1203-1208.	1.6	33
311	Locoregional treatments of unresectable liver metastases from colorectal cancer. <i>Cancer Treatment Reviews</i> , 1998, 24, 3-14.	7.7	12
312	Liver metastases from colorectal cancer. <i>Annals of Oncology</i> , 1997, 8, 393-399.	1.2	4